Dallas-based genetics startup Colossal has raised hundreds of millions from venture capitalists, the CIA, and Peter Thiel. Its ambitious “de-extinction” projects aim to resurrect lost species like the woolly mammoth, Tasmanian tiger, and dire wolf. But critics note the company isn't actually cloning ancient DNA—it's genetically engineering modern relatives to resemble extinct forms.
Despite the hype, some scientists say Colossal's work could yield practical benefits. Advances in gene editing, reproductive technology, and species conservation might emerge from the pursuit. The question remains: will the end result be a genuine conservation tool or an expensive spectacle?